PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10353733-2	1999	We investigated the response of the mitogen-activated protein kinases, extracellular signal-regulated kinases 1 and 2 (ERK1/2), c-Jun-N-terminal kinase 1 (JNK1), and p38, to cisplatin treatment in the ovarian carcinoma cell line SK-OV-3.	Cisplatin	174-183	mitogen-activated protein kinase 1	Homo sapiens	71-117	
10353733-2	1999	We investigated the response of the mitogen-activated protein kinases, extracellular signal-regulated kinases 1 and 2 (ERK1/2), c-Jun-N-terminal kinase 1 (JNK1), and p38, to cisplatin treatment in the ovarian carcinoma cell line SK-OV-3.	Cisplatin	174-183	mitogen-activated protein kinase 3	Homo sapiens	119-125	
10353733-2	1999	We investigated the response of the mitogen-activated protein kinases, extracellular signal-regulated kinases 1 and 2 (ERK1/2), c-Jun-N-terminal kinase 1 (JNK1), and p38, to cisplatin treatment in the ovarian carcinoma cell line SK-OV-3.	Cisplatin	174-183	mitogen-activated protein kinase 8	Homo sapiens	128-153	
10353733-2	1999	We investigated the response of the mitogen-activated protein kinases, extracellular signal-regulated kinases 1 and 2 (ERK1/2), c-Jun-N-terminal kinase 1 (JNK1), and p38, to cisplatin treatment in the ovarian carcinoma cell line SK-OV-3.	Cisplatin	174-183	mitogen-activated protein kinase 8	Homo sapiens	155-159	
10353733-2	1999	We investigated the response of the mitogen-activated protein kinases, extracellular signal-regulated kinases 1 and 2 (ERK1/2), c-Jun-N-terminal kinase 1 (JNK1), and p38, to cisplatin treatment in the ovarian carcinoma cell line SK-OV-3.	Cisplatin	174-183	mitogen-activated protein kinase 1	Homo sapiens	166-169	
10353733-3	1999	Cisplatin caused a late and prolonged induction in a dose-dependent manner of both ERK1/2 and JNK1 activity.	Cisplatin	0-9	mitogen-activated protein kinase 3	Homo sapiens	83-89	
10353733-3	1999	Cisplatin caused a late and prolonged induction in a dose-dependent manner of both ERK1/2 and JNK1 activity.	Cisplatin	0-9	mitogen-activated protein kinase 8	Homo sapiens	94-98	
10353733-4	1999	ERK1/2 and JNK1 activities continued to increase in magnitude up to 24 h following initiation of cisplatin treatment.	Cisplatin	97-106	mitogen-activated protein kinase 3	Homo sapiens	0-6	
10353733-4	1999	ERK1/2 and JNK1 activities continued to increase in magnitude up to 24 h following initiation of cisplatin treatment.	Cisplatin	97-106	mitogen-activated protein kinase 8	Homo sapiens	11-15	
10353733-7	1999	Treatment with cycloheximide resulted in inhibition of cisplatin-induced ERK1/2 activation, demonstrating that ERK1/2 activity induced by cisplatin was dependent on de novo protein synthesis.	Cycloheximide	15-28	mitogen-activated protein kinase 3	Homo sapiens	73-79	
10353733-7	1999	Treatment with cycloheximide resulted in inhibition of cisplatin-induced ERK1/2 activation, demonstrating that ERK1/2 activity induced by cisplatin was dependent on de novo protein synthesis.	Cycloheximide	15-28	mitogen-activated protein kinase 3	Homo sapiens	111-117	
10353733-7	1999	Treatment with cycloheximide resulted in inhibition of cisplatin-induced ERK1/2 activation, demonstrating that ERK1/2 activity induced by cisplatin was dependent on de novo protein synthesis.	Cisplatin	55-64	mitogen-activated protein kinase 3	Homo sapiens	73-79	
10353733-7	1999	Treatment with cycloheximide resulted in inhibition of cisplatin-induced ERK1/2 activation, demonstrating that ERK1/2 activity induced by cisplatin was dependent on de novo protein synthesis.	Cisplatin	55-64	mitogen-activated protein kinase 3	Homo sapiens	111-117	
10353733-7	1999	Treatment with cycloheximide resulted in inhibition of cisplatin-induced ERK1/2 activation, demonstrating that ERK1/2 activity induced by cisplatin was dependent on de novo protein synthesis.	Cisplatin	138-147	mitogen-activated protein kinase 3	Homo sapiens	73-79	
10353733-7	1999	Treatment with cycloheximide resulted in inhibition of cisplatin-induced ERK1/2 activation, demonstrating that ERK1/2 activity induced by cisplatin was dependent on de novo protein synthesis.	Cisplatin	138-147	mitogen-activated protein kinase 3	Homo sapiens	111-117	
10353733-8	1999	Furthermore, inhibition of cisplatin-induced ERK1/2 activity by PD 98059 caused enhanced cisplatin cytotoxicity.	Cisplatin	27-36	mitogen-activated protein kinase 3	Homo sapiens	45-51	
10353733-8	1999	Furthermore, inhibition of cisplatin-induced ERK1/2 activity by PD 98059 caused enhanced cisplatin cytotoxicity.	Cisplatin	89-98	mitogen-activated protein kinase 3	Homo sapiens	45-51	
10353733-10	1999	These observations indicate that ERK1/2 activation induced by cisplatin partially protects cells from cisplatin cytotoxicity.	Cisplatin	62-71	mitogen-activated protein kinase 3	Homo sapiens	33-39	
10353733-10	1999	These observations indicate that ERK1/2 activation induced by cisplatin partially protects cells from cisplatin cytotoxicity.	Cisplatin	102-111	mitogen-activated protein kinase 3	Homo sapiens	33-39	
10353733-11	1999	Continued investigation into the mechanism by which the ERK pathway and other signal transduction pathways modulate the response to cisplatin may be helpful in the development of new strategies for improving the therapeutic use of platinum drugs.	Cisplatin	132-141	mitogen-activated protein kinase 1	Homo sapiens	56-59